Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2017

01-06-2017 | Editorial

Starting a Fixed-Dose Combination Pill versus a Single Agent for Patients with Hypertension

Authors: Edward J. Filippone, MD, FACP, Andrew J. Foy, MD

Published in: Journal of General Internal Medicine | Issue 6/2017

Login to get access

Excerpt

Hypertension remains the number-one cause of morbidity and mortality worldwide,1 and it is well established that treating elevated blood pressure with antihypertensive medications improves these outcomes.2 Target blood pressure values have been promulgated by societies in both Europe and the United States, although large surveys indicate that a significant percentage of patients treated for hypertension do not reach these targets.3 It is now recommended that therapy be initiated with two rather than one medication in individuals with higher pretreatment blood pressure in order to enhance the chances of success.4 , 5 Overall, the most commonly used classes of antihypertensives (i.e., diuretics, beta blockers [BB], calcium channel blockers [CCB], and renin-angiotensin system inhibitors [RASI]) are approximately equally effective in reducing cardiovascular events and mortality.2
Literature
2.
go back to reference Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–1535.CrossRefPubMed Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–1535.CrossRefPubMed
4.
go back to reference Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219. doi:10.1093/eurheartj/eht151.CrossRefPubMed Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219. doi:10.​1093/​eurheartj/​eht151.CrossRefPubMed
5.
go back to reference Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15. doi:10.1097/HJH.0000000000000065.CrossRefPubMed Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15. doi:10.​1097/​HJH.​0000000000000065​.CrossRefPubMed
6.
go back to reference Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41–46. Accessed 12 January 2017.PubMedPubMedCentral Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41–46. Accessed 12 January 2017.PubMedPubMedCentral
7.
10.
go back to reference Lauffenburger JC, Landon JE, Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study. J Gen Intern Med. 2017. doi:10.1007/s11606-016-3972-z.PubMed Lauffenburger JC, Landon JE, Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study. J Gen Intern Med. 2017. doi:10.​1007/​s11606-016-3972-z.PubMed
12.
go back to reference Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J. 2003;326(7404):1427–1431. Accessed 11 January 2017.CrossRef Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J. 2003;326(7404):1427–1431. Accessed 11 January 2017.CrossRef
Metadata
Title
Starting a Fixed-Dose Combination Pill versus a Single Agent for Patients with Hypertension
Authors
Edward J. Filippone, MD, FACP
Andrew J. Foy, MD
Publication date
01-06-2017
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 6/2017
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-017-4013-2

Other articles of this Issue 6/2017

Journal of General Internal Medicine 6/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.